Patient Decision Aid for Antidepressant Use in Pregnancy
Pregnancy, Depression

About this trial
This is an interventional health services research trial for Pregnancy focused on measuring Pregnancy, Depression, Antidepressant Use, Decision Aid
Eligibility Criteria
Inclusion criteria:
- Are females aged >18 years old, and
- Are either planning a pregnancy OR are <30 weeks gestation at enrollment, and
- Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and
- Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale)
Exclusion criteria:
- Have had alcohol or substance abuse or dependence in the previous 12 months, or
- Have active suicidal ideation or psychosis, or
- Are incapable of consenting to participation, or
- Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or
- Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or
- Have a visual impairment that would prevent them from being able to view the website.
Sites / Locations
- Women's College Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Standard Resource Sheet
Electronic Patient Decision Aid
Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.